Trading Halt
Open PDF
| Stock | Immutep Ltd (IMM.ASX) |
|---|---|
| Release Time | 6 Mar 2026, 5:35 p.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Immutep Requests Trading Halt for Futility Analysis
Key Points
- Immutep requests trading halt for announcement on TACTI-004 Phase III trial futility analysis
- Trading halt to remain in place until announcement or until March 11, 2026
- Halt requested to ensure market does not trade on uninformed basis
Full Summary
Immutep Ltd has requested an immediate trading halt in its shares (ASX:IMM) pending an announcement regarding the outcome of the pre-specified interim futility analysis for the TACTI-004 (KEYNOTE-F91) Phase III trial evaluating its lead candidate, Eftilagimod Alfa. The trading halt has been requested to ensure the market does not trade on an uninformed basis. Immutep has requested the trading halt remain in place until the earlier of the announcement of the futility analysis results and the commencement of trading on Wednesday, March 11, 2026. The company is not aware of any other reason why the trading halt should not be granted. Immutep anticipates the trading halt will cease upon it announcing the outcome of the futility analysis.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In